In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Apoptotic and non-apoptotic circulating microparticles in patients with acute coronary syndromes

Session Non-troponin biomarkers in acute coronary syndromes

Speaker Alexios Antonopoulos

Event : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes - Clinical
  • Session type : Abstract Sessions

Authors : E Zacharia (Athens,GR), N Papageorgiou (Athens,GR), AS Antonopoulos (Athens,GR), Z Pallantza (Athens,GR), E Oikonomou (Athens,GR), A Miliou (Athens,GR), CV Mistakidi (Athens,GR), A Kriebardis (Athens,GR), N Orologas (Athens,GR), E Valasiadi (Athens,GR), S Papaioannou (Athens,GR), D Tousoulis (Athens,GR)

E Zacharia1 , N Papageorgiou1 , AS Antonopoulos1 , Z Pallantza1 , E Oikonomou1 , A Miliou1 , CV Mistakidi1 , A Kriebardis1 , N Orologas1 , E Valasiadi1 , S Papaioannou1 , D Tousoulis1 , 1Hippokration General Hospital , 1st Cardiology Department, Athens Medical School - Athens - Greece ,


Background: Circulating microparticles (MP) are surrogate biomarkers of atherosclerosis but their role in patients with acute coronary syndromes (ACS) remain unknown.

Purpose: To explore the levels of apoptotic and non-apoptotic MP in patients with ACS.

Methods: We enrolled a total of 153 patients as follows: 49 patients with STEMI, 35 NSTEMI, 38 with unstable angina (UA), 15 with stable CAD (SCAD) and 16 non-CAD (controls). Flow cytometry analysis was used to quantify circulating apoptotic (annexin+) and non-apoptotic endothelial cell (EMP), red blood cell (RMP) and platelet (PMP) derived microparticles. Circulating C-reactive protein (hsCRP) levels and cardiac troponin I (cTnI) were also assessed. Brachial FMD was also determined as a marker of endothelial function.

Results: There was a stepwise increase in the total number of EMP, RMP and PMP in patients with ACS (STEMI/NSTEMI) compared to UA, SCAD and non-CAD patients. This was mainly explained by the increase in the number of apoptotic EMP, RMP and PMP (a-c), while there were no significant differences in the level of apoptotic EMP, RMP or PMP between patient subgroups (not shown). There was no association between circulating levels of apoptotic or non-apoptotic EMP, RBP or PMP with hsCRP (p=NS for all). Apoptotic EMP only were negatively associated with brachial FMD (rho= -0.185, p=0.04) and positively with cTnI levels (rho= 0.307, p<0.0001).

Conclusions: Circulating apoptotic (but not non-apoptotic) MP are increased in patients with ACS. A negative association is observed between the numbers of circulating apoptotic EMP only and systemic endothelial function. The biological role of circulating apoptotic microparticles’ in the pathogenesis of ACS merits further investigation.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are